First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.

被引：1
|
作者：
Beslija, S. [1 ]
Brodowicz, T. [1 ]
Greil, R. [1 ]
Inbar, M. J. [1 ]
Kahan, Z. [1 ]
Kaufman, B. [1 ]
Lang, I. [1 ]
Steger, G. G. [1 ]
Stemmer, S. M. [1 ]
Zielinski, C. [1 ]
Zvirbule, Z. [1 ]
机构：
[1] CECOG TURANDOT Trialists, Inst Oncol, Sarajevo, Bosnia & Herceg
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/000B-5472.SABCS11-OT2-01-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-01-02
引用
收藏
页数：1
相关论文
共 50 条
  • [41] RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
    Robert, N. J.
    Dieras, V.
    Glaspy, J.
    Brufsky, A.
    Bondarenko, I.
    Lipatov, O.
    Perez, E.
    Yardley, D.
    Zhou, X.
    Phan, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Phase II study of bevacizumab (Bev) combined with weekly paclitaxel (wPac) as first-line therapy for Japanese patients (pts) with HER2-negative metastatic breast cancer (MBC).
    Masuda, N.
    Aogi, K.
    Ohno, S.
    Iwata, H.
    Kashiwaba, M.
    Fujiwara, Y.
    Ito, Y.
    Ueno, T.
    Saijo, N.
    Takashima, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
    Marme, Frederik
    Gerber, Bernd
    Schmidt, Marcus
    Moebus, Volker Jochen
    Foerster, Frank Gerhard
    Grischke, Eva-Maria
    Beckmann, Matthias W.
    Strumberg, Dirk
    Solomayer, Erich
    Klare, Peter
    Windemuth-Kieselbach, Christiane
    Schneeweiss, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
    Koszo, Renata
    Santha, Dra
    Budi, Laszl
    Erfan, Jzsef
    Gyorfy, Karoly
    Horvath, Zsolt
    Kocsis, Judit
    Landherr, Laszlo
    Hitre, Erika
    Mahr, Karoly
    Pajkos, Gabor
    Papai, Zsuzsanna
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 505 - 511
  • [45] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Salvador, J.
    Manso, L.
    de la Haba, J.
    Jaen, A.
    Ciruelos, E.
    de Villena, M. C.
    Gil, M.
    Murias, A.
    Galan, A.
    Jara, C.
    Bayo, J.
    Baena, J. M.
    Casal, J.
    Mel, J. R.
    Blancas, I.
    Sanchez Rvira, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (02): : 160 - 166
  • [46] Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    J. Salvador
    L. Manso
    J. de la Haba
    A. Jaen
    E. Ciruelos
    M. C. de Villena
    M. Gil
    A. Murias
    A. Galan
    C. Jara
    J. Bayo
    J. M. Baena
    J. Casal
    J. R. Mel
    I. Blancas
    P. Sanchez Rvira
    Clinical and Translational Oncology, 2015, 17 : 160 - 166
  • [47] AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
    Gianni, Luca
    Romieu, Gilles H.
    Lichinitser, Michail
    Serrano, Sergio V.
    Mansutti, Mauro
    Pivot, Xavier
    Mariani, Paola
    Andre, Fabrice
    Chan, Arlene
    Lipatov, Oleg
    Chan, Stephen
    Wardley, Andrew
    Greil, Richard
    Moore, Nicola
    Prot, Sylvie
    Pallaud, Celine
    Semiglazov, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1719 - +
  • [48] AVEREL: a randomized Phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer
    不详
    BREAST CANCER MANAGEMENT, 2013, 2 (04) : 274 - 274
  • [49] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Conte, P-F
    Majois, F.
    Espie, M.
    Morand, M.
    Vaissiere, N.
    Villanova, G.
    BRITISH JOURNAL OF CANCER, 2009, 101 (02) : 232 - 237
  • [50] All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
    N Tubiana-Mathieu
    P Bougnoux
    D Becquart
    A Chan
    P-F Conte
    F Majois
    M Espie
    M Morand
    N Vaissiere
    G Villanova
    British Journal of Cancer, 2009, 101 : 232 - 237
12345